🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — LV mass and diastolic function

Echocardiographic changes on GLP-1 — LV mass and diastolic function

Dr.CardioMD Sat, May 30, 2026 at 6:58 AM 20 replies 460 viewsPage 1 of 4
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
May 30, 2026 at 6:58 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. The effect appeared earlier than the weight-loss curve can comfortably explain, which is the basis for arguing that some of the benefit is direct — anti-inflammatory and vascular — rather than purely a consequence of weight.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am trying to establish is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
42 12kim_atl_prep, sarah_TO, wendy_avl and 39 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
May 30, 2026 at 8:02 AM#2
Dr.CardioMD said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

41 11MikeNYC_runner and 38 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
May 30, 2026 at 9:06 AM#3
Dr.CardioMD said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Pushing back on Dr.CardioMD here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Correct me if the detail matters more than I have assumed.

40 10PharmHunterJen, TomTeleRx, DoseLogDan and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
May 30, 2026 at 10:10 AM#4
Dr.SurgeonPGH said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.
Dr.SurgeonPGH said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

39 9DebRD_ATL, KristenIndy, MarkLI_maint and 36 others
Reply Quote Save Share Report
wei_SG
Member
234
890
Nov 2024
Singapore, SG
May 30, 2026 at 4:19 PM#5
PurityPaulOR said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely!

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

Last edited: May 30, 2026 at 5:19 PM
38 8JenPlateau, SallyK_inj, CryptoCarl and 35 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register